Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Endocyte Inc (ECYT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,071,829
  • Shares Outstanding, K 70,330
  • Annual Sales, $ 70 K
  • Annual Income, $ -55,060 K
  • 36-Month Beta 0.31
  • Price/Sales 15,463.65
  • Price/Cash Flow N/A
  • Price/Book 6.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.16
  • Number of Estimates 4
  • High Estimate -0.12
  • Low Estimate -0.18
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +46.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.50 +5.10%
on 10/11/18
18.72 -18.59%
on 09/25/18
-3.13 (-17.04%)
since 09/14/18
3-Month
13.75 +10.84%
on 07/31/18
20.85 -26.91%
on 09/04/18
-2.02 (-11.70%)
since 07/13/18
52-Week
2.81 +442.35%
on 02/06/18
20.85 -26.91%
on 09/04/18
+10.90 (+251.15%)
since 10/13/17

Most Recent Stories

More News
Relatively Good Performance Detected in Shares of Collegium Pharma in the Pharmaceuticals Industry (COLL , PRTK , ECYT, TXMD , LLY )

We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...

COLL : 16.89 (-0.35%)
ECYT : 15.24 (-0.97%)
PRTK : 9.01 (-3.33%)
Endocyte becomes first Purdue startup to reach $1.5B in value

Endocyte Inc.(Nasdaq: ECYT), reached a milestone this year when its value recently reached about $1.5 billion and as the company's drug platforms continue to move through various clinical trials with promising...

ECYT : 15.24 (-0.97%)
Endocyte to Present at Two Investor Conferences on October 2nd

Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company's management team will present at two upcoming...

ECYT : 15.24 (-0.97%)
Top 5 Companies in the Pharmaceuticals Industry with the Best Relative Performance (OMER , ECYT, NKTR , HZNP , SUPN )

We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...

ECYT : 15.24 (-0.97%)
OMER : 14.02 (+0.21%)
NKTR : 49.08 (+0.35%)
First Week of ECYT September 21st Options Trading

Investors in Endocyte Inc saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ECYT options chain...

ECYT : 15.24 (-0.97%)
Endocyte Announces Closing of Public Offering of Common Stock

Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the closing of an underwritten registered public...

ECYT : 15.24 (-0.97%)
Pharma/Biotech Stocks to Watch This Prostate Cancer Month

Here we highlight a few companies that are focused on developing treatments for prostate cancer.

AZN : 37.47 (+0.86%)
JNJ : 133.95 (+0.06%)
ECYT : 15.24 (-0.97%)
ABBV : 89.18 (-1.67%)
TSRO : 40.94 (+0.84%)
PFE : 43.12 (-1.51%)
SNY : 43.43 (+1.26%)
Best Relative Performance in the Pharmaceuticals Industry Detected in Shares of Endocyte Inc (ECYT, AERI , PETX , PCRX , SUPN )

We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...

AERI : 56.24 (+1.57%)
ECYT : 15.24 (-0.97%)
PETX : 5.35 (+1.33%)
Endocyte Announces Pricing of Public Offering of Common Stock

Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the pricing of an underwritten registered public...

ECYT : 15.24 (-0.97%)
Endocyte Announces FDA's Acceptance of Trial Endpoint Change

177Lu-PSMA-617, a prostate specific membrane antigen-targeted radioligand therapy, is Endocyte's (ECYT) lead program. It is being evaluated in a phase III study for mCRPC for PSMA-positive patients

CELG : 81.83 (-0.91%)
LGND : 200.07 (-1.24%)
ECYT : 15.24 (-0.97%)
GILD : 72.78 (-1.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ECYT with:

Business Summary

Endocyte, Inc. is a biopharmaceutical company engaged in the development of therapies for the treatment of cancer and inflammatory diseases. The Company creates novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. Endocyte, Inc. is based...

See More

Key Turning Points

2nd Resistance Point 15.77
1st Resistance Point 15.51
Last Price 15.24
1st Support Level 14.96
2nd Support Level 14.67

See More

52-Week High 20.85
Last Price 15.24
Fibonacci 61.8% 13.96
Fibonacci 50% 11.83
Fibonacci 38.2% 9.70
52-Week Low 2.81

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar